Century Therapeutics company info

What does Century Therapeutics do?

Century Therapeutics (NASDAQ:IPSC) is a biotechnology firm focused on developing innovative therapies to improve the outcomes of cancer patients. Specializing in cellular therapies, Century Therapeutics is pioneering the development of products with the potential to treat not only hematologic cancers but also solid tumors. The company's projects leverage cutting-edge iPSC (induced pluripotent stem cell) technology to manufacture cell therapies that are more effective, accessible, and easier to produce than traditional methods. With a commitment to revolutionizing cancer treatment, Century Therapeutics aims to advance its clinical programs and expand its pipeline to address a broad range of cancers, ultimately striving to bring novel, life-saving treatments to the market.
Century Therapeutics company media

Company Snapshot

Is Century Therapeutics a public or private company?

key

Ownership

Public

How many people does Century Therapeutics employ?

people

Employees

152

What sector is Century Therapeutics in?

pie chart

Sector

Health Care

Where is the head office for Century Therapeutics?

location pin

Head Office

Philadelphia, United States

What year was Century Therapeutics founded?

founded flag

Year Founded

2018

What does Century Therapeutics specialise in?

/Cellular Therapies /Cancer Treatment /Immuno-Oncology /IPSC Technology /Regenerative Medicine /Therapeutic Development

What are the products and/or services of Century Therapeutics?

Overview of Century Therapeutics offerings
iPSC-derived allogeneic cell therapies for cancer, utilizing engineered immune cells to target hematologic and solid tumors.
Development of CNTY-101, an iPSC-derived NK cell product for treating acute myeloid leukemia.
Advancement of CAR-iT cells targeting CD19 for B-cell malignancies, leveraging iPSC technology for scalable production.
Research on engineered iPSC-derived macrophages (CAR-M) for potential treatment of solid tumors, focusing on enhanced phagocytosis.
Collaboration on iPSC-derived T cell therapies for various cancer targets, emphasizing off-the-shelf availability and reduced risk of graft-versus-host disease.
Investment in proprietary engineering platforms to enhance the efficacy, safety, and manufacturability of cell therapy products.

Who is in the executive team of Century Therapeutics?

Century Therapeutics leadership team
  • Photo of Mr. Brent  Pfeiffenberger M.B.A., Pharm.D.
    Mr. Brent Pfeiffenberger M.B.A., Pharm.D.
    CEO & Director
  • Photo of Dr. Adrienne  Farid Ph.D.
    Dr. Adrienne Farid Ph.D.
    Chief Development Officer, CCO & Head of Early Development
  • Photo of Dr. Gregory  Russotti Ph.D.
    Dr. Gregory Russotti Ph.D.
    Chief Technology & Manufacturing Officer
  • Photo of Dr. Morgan  Conn Ph.D.
    Dr. Morgan Conn Ph.D.
    Chief Financial Officer
  • Photo of Dr. Chad A. Cowan Ph.D.
    Dr. Chad A. Cowan Ph.D.
    Chief Scientific Officer
  • Photo of Dr. Shane  Williams Ph.D.
    Dr. Shane Williams Ph.D.
    Chief People Officer
  • Photo of Michael  Naso Ph.D.
    Michael Naso Ph.D.
    Senior VP of Cell Engineering
  • Photo of Dr. Nick  Trede M.D., Ph.D.
    Dr. Nick Trede M.D., Ph.D.
    Senior VP & Head of Clinical Development